Regarding targeted therapy for metastatic breast cancer, limited data suggest that CDK4/6 inhibitors may cause upregulation of IL-6 and IL-8 by tumor cells [87,88], although increases in systemic inflammation have not been documented to our knowledge. This evidence concerns the gene IL6 and neoplasm.